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Abstract
Background: Asthma imposes heavy health burden on children and families worldwide. It is a chronic inflammatory 
airway disease and as such, treatment of the asthmatics is aimed at relieve of bronchoconstriction and inflammation. 
Until about a decade ago, emphasis was on the bronchoconstriction rather than the inflammation.
Objective: To determine the trend in severity of asthma in steroid naive children, in an era when steroid use in the 
treatment of asthma was uncommon.
Materials and Methods: Case notes of patients managed for asthma from 1985 to 1995 and age 5 - 16 years were 
retrieved and reviewed (these case notes are usually stored in Prof. O. Oviawe’s office). Information extracted included 
age of onset of asthma, severity of asthma and drug medication at presentation and at 1 year. The GINA Guideline (2006) 
was used in classifying the asthma severity.
Results: A total of 77 patients satisfied the criteria for the study. Of these, 53 were males and 24 females. Males: Female 
ratio was 2.3:1; age range 5 - 16 years; mean age ± SD (8.5 ± 3.13 years). At presentation, 48 (62.3%) patient had 
intermittent, 29 (37.7%) had persistent asthma, of these, 25 (86.2%) had mild persistent and 4 (13.8%) had moderate 
persistent. None had severe persistent asthma. At 1 year follow-up, 29 (37.7%) now had intermittent asthma, while 
44 (57.1%) had persistent asthma, of these, 23 (52.3%) had mild persistent, 20 (45.5%) had moderate persistent, 
while 1 (2.3%) had severe persistent. Medication therapy was β2-agonist in 72 (93.5%) patients.
Conclusion: The study supports progressive pathologic process possibly inflammatory in origin. It is opined that steroid 
naivity led to the trend seen in this study and judicious use of corticosteroids would have arrested the trend.
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Introduction
Asthma is a chronic inflammatory disease of the airway, and 
is a common ambulatory chest disease in children.[1,2] The 
chronic inflammation makes the airways hyperresponsive 
and labile, leading to variable airway size at different times 
of the day and in response to various stimuli. This feature 
of asthma results in periods of exacerbations and remission 
of symptoms.[1,2]
Most commonly, children with asthma presents with episodic 
cough, wheezing, breathlessness, and chest tightness. The 
severity of the disease depends on the frequency and 
effects of these symptoms and has been classified by Global 
Initiative for Asthma (GINA) into mild intermittent, mild 
persistent, moderate persistent, and severe persistent.[3]
Chronic inflammation is currently recognized to play a 
central role in the initiation and propagation of asthma and 
based on this, several management guidelines are designed 
with different drugs with and without anti‑inflammatory 
effects. Of all these, corticosteroids have been used 
worldwide for the treatment of both chronic asthma 
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and acute exacerbations, and their benefits are now 
widely accepted and corticosteroid are now seen as drug 
of choice.[3‑6]
Despite the known beneficial effect of steroids, there is 
an apparent delay in its commencement by physicians 
treating childhood asthma. This steroid naivety may be 
due to the fear of side‑effects which may include increase 
in susceptibility to infection, reduction in lung growth,[7‑9] 
and most importantly defective linear growth.[10‑14]
This study sets out to evaluate the practice concerning 
management of children with asthma in University of Benin 
Teaching Hospital (UBTH), Benin City at a period when 
steroid use was uncommon.
Materials and Methods
Case note of patients aged 5‑16 years, managed for asthma 
and attended the asthma clinic at the UBTH between 1985 
and 1995 were retrieved and reviewed in 2010. Information 
extracted includes age, gender, age of onset of the asthma, 
drug therapy, and asthma severity level at presentation and 
1‑year follow‑up. Twelve patients that were found to have 
had corticosteroids during the course of treatment were 
excluded from the study. Asthma diagnosis and severity 
level were based on GINA recommendations. The data 
were entered into Excel version 2007 and later transported 
to Statistical Package for Social Sciences (SPSS) version 16 
for analysis.
Results
Characteristics of the subject
Of the 89 patients reviewed, 77 patients met the criteria 
for the study. Of these 77, 53 were male patients and 
24 female patients, male:female ratio of 2.3:1, whereas the 
age (Mean ± SD; range) was 8.5 ± 3.13; 5‑16 years.
Figure 1 shows the severity of the asthma at presentation 
and 1 year later. Of 77 subjects at presentation, 48 (62.3%) 
patients had intermittent, 29 (37.7%) patients had persistent 
asthma, of these, 25 (86.2%) patients had mild persistent 
and 4 (13.8%) patients had moderate persistent. None had 
severe persistent asthma. At 1‑year follow‑up, 29 (37.7%) 
patients now had intermittent asthma whereas 44 (57.1%) 
patients had persistent asthma, of these, 23 (52.3%) patients 
had mild persistent, 20 (45.5%) patients had moderate 
persistent, whereas 1 (2.3%) patient had severe persistent 
asthma.
Figure 2 shows that 48.1% of those patients with asthma 
got worse and down regulated to other grades. 39% patients 
showed no change, and only 7.8% patients improved. From 
the pie chart [Figure 3], 43.8% patients had persistent 
asthma, 47.9% patients had no change and 4% patients 
had incomplete data.
Table 1 shows that majority 72 (93.5%) of the patients at 
presentation were on β2‑agonist alone. At 1‑year follow‑up, 
69 (89.6%) patients were still on β2‑agonist alone. From 
Table 1, other drugs like theophylline were added to the 
Figure 1: Severity of asthma at various periods
Figure 2: Pattern of change in asthma severity in 77 patients at 
1-year follow-up
Figure 3: Pattern of change at 1 year in 48 patients who had 
intermittent asthma at presentation
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β2‑agonist in 12 (15.6%) at 1‑year follow‑up compared to 
8 (10.4%) patients at presentation.
Discussion
At presentation, majority of the asthmatic children (48%) 
of the subjects had mild intermittent asthma, only 29% 
patients had persistent asthma. It is obvious that at the 
onset of this evaluation, the intermittent asthma was 
more common compared to the persistent. However, this 
changed at 1‑year follow‑up, with more of the subjects 
now having persistent type of asthma. What this suggests 
is that, corticosteroid naive asthmatic children worsened 
progressively from intermittent to persistent asthma. Most 
of these corticosteroid naive children with intermittent 
asthma based on the (2002 GINA Guideline) were only 
given short acting β2‑agonist. From the foregoing, one 
can speculate that without doing anything about the 
inflammation, the subjects are likely to down regulate and 
develop persistent asthma. This trend of progression with 
or without steroid therapy was demonstrated by Tamesis 
and coworkers.[15] In this study, they claimed that no drug 
in our current armamentarium, however, has been found 
to alter the natural progression of childhood asthma nor 
halt progressive airway damage in the more susceptible 
children.[15]
The index evaluation also revealed that the mode of 
treatment did not follow the GINA guideline as there was 
naivety in starting steroids for cases of persistent asthma.[3] 
The reason for this delay in the use of steroids, may be 
due to fear of known side‑effects of steroids. Although 
topical airway corticosteroid therapy has improved the 
control of asthma markedly while lessening the risk of 
corticosteroid side‑effects, the use of inhaled corticosteroids 
continue to be accompanied by a fear of potential adverse 
systemic effects.[16‑18] Unfortunately, these fears results in 
some children being deprived of appropriate and effective 
treatment or even being exposed to a greater risk of periodic 
oral corticosteroid treatment.[16‑18] This finding agrees 
exactly with our finding in the index evaluation.
Nevertheless, because these agents may be used for a 
long period of time in a large number of children, safety 
issues are paramount. Thus, inhaled corticosteroid used 
in small doses presents less significant risks for systemic 
side‑effects. Use of higher doses of inhaled corticosteroid 
and systemic corticosteroids are associated with significant 
side‑effects.[19,20]
Furthermore, the finding in this evaluation shows that 
majority of subjects were on β2‑agonist at onset and at 
1‑year follow‑up, although, some of the subjects that were 
only on β2‑agonist at onset now had theophylline added at 
1‑year. This mode of therapy was continued even in the face 
of worsening severity.
Based on these findings, it is obvious that without doing 
anything about the inflammation, the subjects are likely to 
down‑regulate and develop persistent asthma. Although, 
Tamesis and coworkers in their study found that even with 
steroids, those that are predisposed will still down‑regulate,[15] 
some authors have suggested that early intervention with 
corticosteroids in patients with newly diagnosed asthma 
is associated with a better preservation of lung function 
than when steroid treatment is withheld for some years.[19] 
They were of the opinion that if untreated the allergic 
inflammation would probably lead to chronic changes of 
the bronchial wall. They argued for an early institution and 
aggressive treatment with inhaled steroids.[21,22] This study 
showed progressive worsening of the disease over time in 
steroid naïve patients.
In the management of children with asthma, the beneficial 
use of steroids in asthmatic children has been known for 
a long time.[10‑14] With the increasing knowledge of the 
side‑effects of systemically administered steroids, there has 
been a steady increase in the use of inhaled steroids, and 
they are presently considered to be the most important 
treatment for asthma and have formed the cornerstone for 
most of the treatment guidelines worldwide.[10‑14]
It is also shown from this study that more subjects were on 
β2‑agonist at onset and at 1‑year follow‑up, even in the face 
of worsening severity.
Conclusion
From our study, majority of the children with asthma had 
mild intermittent asthma at presentation. However, this 
severity progressed to persistent asthma in majority (57.1%) 
of patients at 1‑year follow‑up.
The most common form of persistent asthma from our 
study is mild persistent asthma at both presentation and at 
1‑year follow‑up. Severe persistent asthma was uncommon 
in our study.
The severity trend found in this study supported a 
progressive pathological process which is assumed to be 
inflammatory in origin.
Table 1: Medication* for the asthma at presentation 
and at 1-year follow-up
Medication Onset 1-year follow-up
N %# N %#
β
2
-Agonist 72 93.5 69 89.6
Theophylline 12 15.6 3 3.9
β
2
 agonist plus theophylline 8 10.4 12 15.6 
Nil 3 3.9 0 –
*Multiple medication in some cases, #Based on 77 patients
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It is therefore concluded that failure to initiate prompt 
and sustained corticosteroid therapy may contribute to the 
severity progression trend.
Limitation of Study
Due to lack of records, longer periods of follow‑up was not 
possible, this would have enhanced our knowledge on what 
eventually happened to the subjects in this study.
Line of Future Research
A possible prospective study designed to compare those that 
were started on steroids with those on only bronchodilators.
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